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Abstract. Immigrants returning home to visit friends and relatives (VFR travelers) are at higher risk of travel-
associated illness than other international travelers. We evaluated 3,707 VFR and 17,507 non-VFR travelers seen for
pre-travel consultation in Global TravEpiNet during 2009–2011; all were traveling to resource-poor destinations. VFR
travelers more commonly visited urban destinations than non-VFR travelers (42% versus 30%, P < 0.0001); 54% of VFR
travelers were female, and 18% of VFR travelers were under 6 years old. VFR travelers sought health advice closer to
their departure than non-VFR travelers (median days before departure was 17 versus 26, P < 0.0001). In multivariable
analysis, being a VFR traveler was an independent predictor of declining a recommended vaccine. Missed opportunities
for vaccination could be addressed by improving the timing of pre-travel health care and increasing the acceptance of
vaccines. Making pre-travel health care available in primary care settings may be one step to this goal.
INTRODUCTION
Approximately 12% of the United States population are
foreign-born, and another 11% are native-born with at least
one foreign-born parent.1 Members of this immigrant popula-
tion who are traveling home to visit friends or relatives in
lower-income countries (VFR travelers) are at higher risk of
travel-related infectious diseases than the general population
of international travelers.2,3 In US surveillance data from
2010, 71% of imported malaria cases in travelers with an
identified purpose of travel were VFR travelers.4 These VFR
travelers with malaria were significantly less likely to have
taken chemoprophylaxis than individuals traveling for other
purposes. As with malaria, the majority of travel-associated
typhoid fever cases in the United States in 1999–2006 also
occurred in VFR travelers.5 Enteric (typhoid and paraty-
phoid) fever was the most common vaccine-preventable dis-
ease among ill returned travelers seen over a decade by the
GeoSentinel Surveillance Network.6 VFR travel, particularly
to South Central Asia, was an independent risk factor for
enteric fever in this population. Other infectious diseases,
including hepatitis A, measles, tuberculosis, and others, are
also more common in VFR travelers.6–9
There are multiple potential reasons for the increased risk
of travel-related illness in VFR travelers, including lower
socioeconomic status, language barriers, behavioral differ-
ences while traveling, and presumption of immunity to infec-
tions found at the travel destinations. Disease prevention
strategies for VFR travelers are a public health priority and
are aimed at decreasing the burden of illness in this population
as well as at curbing the global spread of infectious diseases.10,11
Primary care practitioners are the most common source of pre-
travel health advice for VFR travelers,12 although airport sur-
veys of departing travelers have repeatedly shown that many
VFR travelers do not seek pre-travel health advice.12–14
Here, we evaluate a large cohort of VFR travelers who
obtained pre-travel health advice within Global TravEpiNet, a
consortium of US practices that provide care to international
travelers. Our goal was to better understand the demographics,
itineraries, and pre-travel health care of VFR travelers who
sought pre-travel health advice and identify areas in which the
care of this population could be improved.
METHODS
Global TravEpiNet clinics. Global TravEpiNet is a con-
sortium of US practices that is sponsored by the Centers
for Disease Control and Prevention (CDC) as previously
described.15 Global TravEpiNet sites are distributed across
the United States and include academic practices, health care
consortia, health maintenance organizations, pharmacy-based
clinics, private practices, and public health clinics. An institu-
tional review board at each participating site reviewed and
approved the study.
Study population. Clinicians collected data on all individ-
uals seen for pre-travel consultation at participating sites from
January of 2009 to December of 2011 using a secure internet
tool. For each unique clinic visit, travelers provided details
about their medical history, itinerary, and travel purpose.
Clinicians verified the information provided by travelers
and entered additional data on immunization history, health
advice provided, vaccines administered, and medications
prescribed during the pre-travel encounter. If a traveler had
an indication for a vaccine according to CDC guidelines that
were current at the time of the clinic visit, but the vaccine
was not administered, the clinician was required to provide a
reason for not administering the vaccine; available options
included pre-existing immunity, vaccine not indicated,
referred to primary care provider for vaccination, patient
declined, medical contraindication, insufficient time, or vac-
cine not available.
Data analysis. Geographic destinations were classified into
regions according to the grouping of member states of the
World Health Organization (WHO) (http://www.who.int/about/
regions/en/index.html) and income categories (low income,
lower middle income, upper middle income, or high income)
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according to the 2009World BankWorld Development Report
(http://econ.worldbank.org).16 For purposes of analysis, we
considered travel to low- or lower middle-income (LLMI)
countries to be highest risk, and travelers to these two desti-
nation categories were considered together. Countries with
risk of malaria or yellow fever transmission were defined in
accordance with the CDC categorization for the time period
of the study.2,17 We accounted for the revised yellow fever
vaccine recommendations for those individuals traveling after
April 1, 2011 in our definition of destinations requiring yellow
fever vaccine.2
Travelers selected one or more of the following purposes for
their trip: leisure, business, returning to region of origin of self
or family to visit friends and relatives, adoption, providing
medical care, receiving medical care, research/education, non-
medical service work, missionary work, military service, adven-
turing, attending large gathering or event, or other activities.
Travelers also provided information regarding the planned
accommodations for their trip. In accordance with the CDC
definition of the term,2 we defined a VFR traveler as an indi-
vidual who was traveling to an LLMI country and who (1)
selected “traveling to region of origin of self or family to visit
friends or relatives” as their purpose of travel or (2) stated that
they would be pursuing a home stay with relatives on their trip.
For the present analysis, we compare VFR travelers with trav-
elers to LLMI countries who were traveling for other purposes.
Data analyses were performed using Stata 12.0 (StataCorp,
College Station, TX) and Excel 2003 (Microsoft Corporation,
Redmond, WA). We used Kruskal–Wallis equality of pro-
portions test, Somers’ D test, and separate random intercept
logistic regressions with clinical site as the random effect to
evaluate measures of association and statistical significance in
the data. We also performed multivariable logistic regression
analyses to examine the effect of individual variables on the
likelihood of declining a vaccine using random effects esti-
mation to account for variances by clinical site. We analyzed
the following variables in the logistic regression: traveler’s
age (³ 18 versus < 18 years), duration of travel (> 28 versus
£ 28 days), sex, region of birth, number of medical concerns
(³ 2 versus < 2), region of destination, reason for visiting the
clinic, and purpose of travel. For analyzing vaccine declina-
tions, we compared travelers who received the vaccine in
association with the clinic visit with those travelers who
declined to be vaccinated.
RESULTS
We included 3,707 VFR and 17,507 non-VFR travelers in
our analysis; all were traveling to an LLMI country as defined
by the World Bank. Females comprised a slight majority
(54%) of both VFR and non-VFR travelers seen at Global
TravEpiNet sites. VFR travelers were significantly younger
than non-VFR travelers (median age = 30 years versus
37 years, P < 0.001); 18% of VFR travelers were younger than
6 years of age (Table 1), whereas < 1% of non-VFR travelers
were in this age category. VFR travelers pursued trips of
longer duration than non-VFR travelers (median duration =
25 days versus 14 days, P < 0.001) and were more likely to visit
only urban areas (42% versus 30%, P < 0.0001) (Table 1).
Among travelers to Africa, VFR travelers were particularly
likely to visit only urban areas (42% of VFR travelers versus
19% of non-VFR travelers to the WHO African region, P <
0.01). VFR travelers also sought pre-travel health care closer
to their departure date than non-VFR travelers (median =
17 days versus 26 days prior to departure, P < 0.001) (Table 1).
Overall, VFR travelers were more likely than non-VFR
travelers to visit countries with regions endemic for malaria
or yellow fever. For VFR travelers, the most frequently visited
regions were the WHO regions of Africa (46%), Southeast
Asia (26%), and the Western Pacific (18%). For non-VFR
travelers to LLMI countries, Africa (31%), Southeast Asia
(30%), and the Western Pacific (22%) were also the most
Table 1
Demographic and travel-related characteristics of VFR travelers
compared with non-VFR travelers at Global TravEpiNet from
January of 2009 to December of 2011
VFR Non-VFR P value*
Number 3,707 17,507
Age (years)
< 1 107 (2.9%) 7 (< 0.1%) 0.001
1–5 556 (15.0%) 83 (0.5%) 0.001
6–17 550 (14.8%) 784 (4.5%) 0.001
18–49 1,820 (49.1%) 11,080 (63.3%) 0.001
50–64 498 (13.4%) 3,822 (21.8%) 0.001
> 65 176 (4.8%) 1,731 (9.9%) 0.001
Sex (female) 2,002 (54.0%) 9,519 (54.3%) 0.86
Travel duration
1–7 days 108 (2.9%) 2,320 (13.3%) < 0.0001
8–14 days 747 (20.1%) 7,150 (40.8%) < 0.0001
15–28 days 1,165 (31.4%) 5,011 (28.6%) < 0.0001
29–180 days 1,545 (41.7%) 2,488 (14.2%) < 0.0001
> 6 months 136 (3.7%) 526 (3.0%) < 0.0001
Type of destination
Urban only 1,542 (41.6%) 5,116 (29.2%) < 0.0001
Rural only 136 (3.7%) 1,847 (10.6%) < 0.0001
Both 2,015 (54.4%) 10,530 (60.2%) < 0.0001




17 (8–33) 26 (12–46) 0.0001
Top five destination countries
India (18.1%) India (17.9%)
Ghana (8.3%) China (10.5%)
Ethiopia (6.0%) Thailand (9.3%)
Nigeria (5.9%) Kenya (8.4%)
Vietnam (5.6%) Tanzania (8.3%)
*Based on Kruskal–Wallis equality-of-proportions test or Somers’ D test as appropriate,
adjusted for clustering among clinical sites.
Table 2
Medical conditions of VFR travelers compared with non-VFR
travelers at Global TravEpiNet from January of 2009 to
December of 2011
Medical condition VFR N (%) Non-VFR N (%) P value*
Any medical condition 2,204 (54.6) 10,683 (61.0) < 0.001
Seasonal allergies 987 (26.6) 5,630 (32.2) < 0.001
Heart/cardiovascular 528 (14.2) 3,218 (18.4) < 0.001
Neurological/psychiatric 222 (6.0) 1,759 (10.1) < 0.001
Lung 326 (8.8) 1,382 (7.9) 0.24
Cancer or blood disorder 182 (4.9) 1,252 (7.2) < 0.001
Endocrine disorder 259 (7.0) 1334 (7.6) 0.45
Diabetes 121 (3.3) 347 (2.0) < 0.001
Intestinal system 173 (4.7) 1,137 (6.5) < 0.001
Dermatologic 218 (5.9) 1,091 (6.2) 0.29
Joint 165 (4.5) 995 (5.7) 0.001
Immune system 132 (3.6) 392 (2.8) 0.005
Obstetric/gynecologic 128 (6.4) 424 (4.5) 0.043
Pregnant/breastfeeding 45 (2.3) 65 (0.7) < 0.001
Kidney 74 (2.0) 289 (1.7) 0.17
Liver 83 (2.2) 192 (1.1) < 0.001
*Based on random intercept logistic regressionmodels with clinical site as the random effect.
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commonly visited regions. India, Ghana, Ethiopia, Nigeria, and
Vietnam were the most common destination countries for
VFR travelers; aside from India, none of these countries were
among the top destinations of non-VFR travelers (Table 1).
VFR travel took place most frequently (29% of trips) in the
summer months of the northern hemisphere.
VFR travelers had fewer existing medical condition than
non-VFR travelers (Table 2). The types of medical conditions
also differed between VFR and non-VFR travelers. In partic-
ular, VFR travelers were more likely to be pregnant or breast-
feeding, and diabetes and immune system disorders were
more common in VFR travelers than non-VFR travelers.
VFR travelers were less likely to report a neuropsychiatric
condition than non-VFR travelers. On average, VFR trav-
elers were taking fewer medications than non-VFR travelers
(VFR median = 0, interquartile range [IQR] = 0–1; non-VFR
median = 1, IQR = 0–2; P < 0.001).
We evaluated the malaria chemoprophylaxis agent that was
prescribed to travelers going to countries with regions that are
endemic for malaria (Table 3). Atovaquone/proguanil was
the most commonly prescribed chemoprophylaxis agent for
both VFR and non-VFR travelers; however, a much higher
proportion of VFR travelers than non-VFR travelers received
mefloquine (30.2% versus 3.6%; P < 0.001). VFR travelers
more commonly received mefloquine than non-VFR trav-
elers when traveling for 28 days or fewer (17.5% versus 2.5%;
P < 0.001) and when traveling for 7 days or fewer (12.7%
versus 1.6%; P < 0.001). VFR travelers were less likely than
non-VFR travelers to receive prescription antibiotics for trav-
elers’ diarrhea (72.6% versus 91.4%; P < 0.001).
VFR travelers were more likely than non-VFR travelers to
have existing immunity to hepatitis A at the time of their
pre-travel consultation (47% versus 40%; P < 0.001). Typhoid,
hepatitis A, and yellow fever were the three most frequently
administered vaccines among VFR travelers and non-VFR
travelers alike (administered to 74%, 41%, and 34% of VFR
travelers, respectively, and 76%, 55%, and 26% of non-
VFR travelers, respectively).
Clinicians were required to provide a reason when vaccines
were not administered to travelers to whom they would be
otherwise indicated by the current CDC guidelines at the time
of the visit. In most (95%) cases, declination by the traveler
was cited as the reason for not administering a vaccine. Refer-
ral to another provider, medical contraindication, insufficient
time to complete the vaccine series before departure, and lack
of availability of vaccine were other reasons that were cited
less frequently (< 5%). We performed a multivariable analysis
to identify predictors of declining any recommended vaccine
in the study population. Being a VFR traveler (odds ratio
[OR] = 1.30, 95% confidence interval [CI] = 1.15–1.48), trav-
eling for > 28 days (OR = 1.72, 95% CI = 1.56–1.89), traveling
to the WHOAfrican region (OR = 1.21, 95% CI = 1.08–1.35),
being an adult (OR = 1.54, 95% CI = 1.32–1.78), and having
fewer than two medical concerns (OR = 1.23, 95% CI = 1.13–
1.34) were each independently associated with declining a
recommended vaccine. In particular, 10% of VFR travelers
traveling to yellow fever-endemic countries who were offered
the yellow fever vaccine declined it, and 85% of VFR trav-
elers who were offered rabies vaccine declined it (Figure 1).
In contrast, 4% of non-VFR travelers visiting yellow fever-
endemic countries who were offered the yellow fever vaccine
declined it, and 59% of non-VFR travelers who were offered
rabies vaccine declined it.
Table 3
Malaria chemoprophylaxis in VFR travelers compared with non-
VFR travelers traveling to countries that include regions endemic
for malaria
VFR N (%) Non-VFR N (%) P value
Antimalarial (any) 2,724 (74.7)* 12,172 (72.0)† < 0.0001
Atovaquone/proguanil 1,260 (34.8) 9,325 (55.6)
Mefloquine 1,092 (30.2) 606 (3.6)
Chloroquine 115 (3.2) 1,108 (6.6)
Doxycycline 192 (5.0) 838 (5.0)
Primaquine 0 (0) 5 (< 0.1)
*Sixty-five travelers received more than one prescription or could not be classified.
†Two hundred ninety travelers received more than one prescription or could not be classified.
Figure 1. Proportion of VFR travelers and non-VFR travelers declining selected indicated vaccines at Global TravEpiNet from January of
2009 to December of 2011. The total number of individuals who were administered or declined the vaccine is shown above each column.
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DISCUSSION
According to the US Office of Travel and Tourism Indus-
tries, 35% of US overseas travelers in 2010 (approximately
10 million travelers) reported visiting friends and relatives as
the main purpose of their trip. VFR travelers have repeatedly
been identified as a group at higher risk of travel-associated
illness,3,7 and prevention strategies targeted at this population
are a public health priority.10 Knowledge about existing health
conditions, planned itineraries, and pre-travel health care of
this large traveling population has been limited to date.
We identified a number of epidemiologically important
characteristics of VFR travelers seen at Global TravEpiNet
sites. Slightly more female VFR travelers than male VFR
travelers were seen for pre-travel health advice. This finding
may relate to the fact that women are more likely than men to
pursue pre-travel health advice.18 Alternatively, women might,
in fact, comprise a majority of VFR travelers. Data from
the Office of Travel and Tourism Industries from 2010 indi-
cate that 54% of all US leisure and VFR travelers in 2010
were female19—similar to the proportion identified in Global
TravEpiNet. VFR travelers were also significantly younger
than non-VFR travelers. In particular, 33% of VFR travelers
seen at Global TravEpiNet sites were children, and 18% were
children under the age of 6 years. In contrast, children com-
prised only 8% of all US international travelers in 2010.19
Ease of travel and increased global migration, with a conse-
quent desire to bring children to visit relatives, are likely
important reasons why children comprise such a high propor-
tion of VFR travelers. Recent data from the GeoSentinel
Network indicate that children are at higher risk of complica-
tions from illness acquired while traveling. In an analysis of
10 years of data, 14% of children with travel-related illness
required hospitalization compared with 10% of adults.20
In addition to age and sex, there were other important
distinctions in itinerary and pre-travel health care between
VFR and non-VFR travelers in this study. VFR travelers
pursued trips of significantly longer duration, with the major-
ity of itineraries being 1 month or longer. Long-term travel
is associated with a unique profile of health risks, including
vector-borne illness, contact-transmitted diseases, and psy-
chological problems.21 Importantly, VFR travelers sought
pre-travel health advice closer to their departure date than
non-VFR travelers—a factor that can limit the ability to
complete needed vaccine series. VFR travelers, particularly
travelers to the WHO African region, also visited urban des-
tinations more frequently than non-VFR travelers. Patterns of
disease risk, including vector-borne disease, zoonotic disease,
and trauma, may differ between urban and rural areas, and
this finding should be considered during pre-travel counseling.
The itineraries of VFR travelers frequently included areas
endemic for malaria, with countries in the WHO African
region representing almost one-half of all destinations of
VFR travelers. In 2010, 65% of imported malaria cases in
the United States with a known region of acquisition were
acquired in Africa.4 Lack of malaria chemoprophylaxis or
non-adherence to a prescribed prophylactic was common
among these imported malaria case patients. By definition,
travelers in this cohort all sought pre-travel health care and
were offered malaria chemoprophylaxis based on their
itinerary. Notably, mefloquine was disproportionately pre-
scribed to VFR travelers compared with non-VFR travelers,
regardless of duration of travel. Although less costly, meflo-
quine has higher rates of gastrointestinal and neuropsychiat-
ric adverse effects compared with other chemoprophylaxis
agents,22 particularly among women.23 Identifying optimal
strategies for chemoprophylaxis uptake and compliance among
VFR travelers, particularly those travelers visiting Africa, is
a priority.
Declining recommended vaccines was remarkably common
among VFR travelers in this cohort, especially considering
that these individuals had sought pre-travel health care. Trav-
elers visiting Africa were particularly likely to decline a rec-
ommended vaccine. Declination of recommended vaccines
among VFR travelers may relate to cost, concerns about vac-
cine safety, delayed timing of the pre-travel visit, or lack of
perceived risk. Our results indicate that strategies to improve
travel vaccine uptake in the VFR population, even among those
travelers who seek pre-travel health care, are needed.
An important limitation of our study is that VFR travelers,
in general, infrequently seek specialized pre-travel health
advice12; travelers seen at Global TravEpiNet sites may,
therefore, differ from the overall population of VFR trav-
elers. Nevertheless, even within the population seeking spe-
cialized pre-travel care, we were able to identify relevant
characteristics of VFR travelers that may affect health out-
comes and are appropriate targets for public health interven-
tions. In particular, outreach targeted at women and children,
who comprise a substantial proportion of VFR travelers, is
needed. Our data suggest that missed opportunities for vacci-
nation in VFR travelers can be addressed by improving the
timing of pre-travel health care and increasing the acceptance
of recommended vaccines. Making pre-travel health care avail-
able in more affordable and accessible primary care settings
may be one important step to this goal; our findings, in con-
junction with geographic data from the US census, could help
target these efforts to appropriate immigrant communities.
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